NCT00389987

Ertapenem Sodium vs. Piperacillin/Tazobactam in the Treatment of Complicated Intra-Abdominal Infections (0826-037)

A Prospective, Multicenter, Double-Blind With In-House Blinding, Randomized, Comparative Study to Evaluate the Efficacy, Safety, and Tolerability of Ertapenem Sodium Versus Piperacillin/Tazobactam in the Treatment of Complicated Intra-Abdominal Infections in Hospitalized Adults

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 300 (planned)
• Sponsor: Merck Sharp & Dohme LLC · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is designed to compare the efficacy of ertapenem and piperacillin/tazobactam with respect to the clinical response in baseline microbiologically evaluable patients; and to evaluate the tolerability and safety of ertapenem compared to piperacillin/tazobactam.

Detailed description

Original label approved November 2001

Conditions

• Complicated Intra-Abdominal Infections

Interventions

Type	Name	Description
DRUG	MK0826, /Duration of Treatment : 8 Weeks
DRUG	Comparator : piperacillin sodium (+) tazobactam sodium /Duration of Treatment : 8 Weeks

Timeline

• Start date: 2001-09-01
• Primary completion: 2004-05-01
• Completion: 2004-05-01
• First posted: 2006-10-19
• Last updated: 2017-02-17